Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Steve Scala is an analyst at TD Cowen. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/27/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10/07/2024 | ABBV | Buy Now | AbbVie | $204.00 | 10.29% | Steve Scala69% | $195 → $225 | Maintains | Buy | Get Alert |
| 10/07/2024 | BMY | Buy Now | Bristol-Myers Squibb | $59.93 | -1.55% | Steve Scala69% | $53 → $59 | Maintains | Hold | Get Alert |
| 08/12/2024 | AZN | Buy Now | AstraZeneca | $73.70 | 28.9% | Steve Scala69% | $90 → $95 | Maintains | Buy | Get Alert |
| 08/12/2024 | BMY | Buy Now | Bristol-Myers Squibb | $59.93 | -11.56% | Steve Scala69% | $45 → $53 | Maintains | Hold | Get Alert |
| 01/04/2024 | MRK | Buy Now | Merck & Co | $89.23 | 51.29% | Steve Scala69% | $125 → $135 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/04/2024 | PFE | Buy Now | Pfizer | $25.15 | 27.24% | Steve Scala69% | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $59.93 | 10.13% | Steve Scala69% | $80 → $66 | Maintains | Market Perform | Get Alert |
| 09/12/2023 | RHHBY | Buy Now | Roche Holding | $41.94 | -4.63% | Steve Scala69% | $45 → $40 | Maintains | Market Perform | Get Alert |
| 05/23/2023 | LLY | Buy Now | Eli Lilly | $820.60 | -39.07% | Steve Scala69% | $430 → $500 | Maintains | Outperform | Get Alert |
| 12/05/2022 | LLY | Buy Now | Eli Lilly | $820.60 | -47.6% | Steve Scala69% | $390 → $430 | Maintains | Outperform | Get Alert |
| 11/15/2022 | RHHBY | Buy Now | Roche Holding | $41.94 | 14.45% | Steve Scala69% | → $48 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/27/2022 | RHHBY | Buy Now | Roche Holding | $41.94 | 14.45% | Steve Scala69% | $58 → $48 | Maintains | Outperform | Get Alert |
| 04/22/2022 | EQRX | Buy Now | EQRx | — | — | Steve Scala69% | — | Initiates | → Outperform | Get Alert |
| 04/14/2022 | ABBV | Buy Now | AbbVie | $204.00 | -11.76% | Steve Scala69% | $150 → $180 | Maintains | Outperform | Get Alert |
| 01/18/2022 | ABBV | Buy Now | AbbVie | $204.00 | -26.47% | Steve Scala69% | $130 → $150 | Maintains | Outperform | Get Alert |
| 08/30/2021 | LLY | Buy Now | Eli Lilly | $820.60 | -63.44% | Steve Scala69% | $250 → $300 | Maintains | Outperform | Get Alert |
| 08/23/2021 | ABBV | Buy Now | AbbVie | $204.00 | -36.27% | Steve Scala69% | $120 → $130 | Maintains | Outperform | Get Alert |
| 07/22/2021 | RHHBY | Buy Now | Roche Holding | $41.94 | — | Steve Scala69% | — | Initiates | → Outperform | Get Alert |
| 06/24/2021 | LLY | Buy Now | Eli Lilly | $820.60 | -69.53% | Steve Scala69% | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/03/2021 | OGNw | Buy Now | Organon | — | — | Steve Scala69% | → $40 | Initiates | → Market Perform | Get Alert |
| 02/12/2021 | LLY | Buy Now | Eli Lilly | $820.60 | -71.36% | Steve Scala69% | $195 → $235 | Maintains | Outperform | Get Alert |
| 02/01/2021 | NVS | Buy Now | Novartis | $112.57 | -6.72% | Steve Scala69% | $110 → $105 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/10/2020 | ABBV | Buy Now | AbbVie | $204.00 | -41.18% | Steve Scala69% | $105 → $120 | Maintains | Outperform | Get Alert |
| 07/13/2020 | RPRX | Buy Now | Royalty Pharma | $31.37 | 75.33% | Steve Scala69% | → $55 | Initiates | → Outperform | Get Alert |
| 04/15/2020 | LLY | Buy Now | Eli Lilly | $820.60 | -80.5% | Steve Scala69% | $145 → $160 | Maintains | Outperform | Get Alert |
| 02/18/2020 | ABBV | Buy Now | AbbVie | $204.00 | -48.53% | Steve Scala69% | $98 → $105 | Maintains | Outperform | Get Alert |
| 02/18/2020 | ABBV | Buy Now | AbbVie | $204.00 | -48.53% | Steve Scala69% | $98 → $105 | Maintains | Outperform | Get Alert |
| 12/26/2019 | ABBV | Buy Now | AbbVie | $204.00 | -51.96% | Steve Scala69% | $90 → $98 | Reiterates | → Outperform | Get Alert |
| 12/26/2019 | ABBV | Buy Now | AbbVie | $204.00 | -51.96% | Steve Scala69% | $90 → $98 | Maintains | Outperform | Get Alert |
| 11/26/2018 | NVS | Buy Now | Novartis | $112.57 | -11.17% | Steve Scala69% | → $100 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/11/2017 | ABBV | Buy Now | AbbVie | $204.00 | — | Steve Scala69% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 04/05/2017 | NVS | Buy Now | Novartis | $112.57 | -31.6% | Steve Scala69% | $87 → $77 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/06/2016 | ABBV | Buy Now | AbbVie | $204.00 | — | Steve Scala69% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/05/2015 | NVS | Buy Now | Novartis | $112.57 | -6.72% | Steve Scala69% | $95 → $105 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/03/2014 | LLY | Buy Now | Eli Lilly | $820.60 | -91.71% | Steve Scala69% | $61 → $68 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/15/2013 | ABBV | Buy Now | AbbVie | $204.00 | — | Steve Scala69% | — | Initiates | → Outperform | Get Alert |
| 10/12/2012 | LLY | Buy Now | Eli Lilly | $820.60 | — | Steve Scala69% | — | Downgrade | Neutral → Underperform | Get Alert |
